Lecrolyn

Sodium Cromoglicate, the active ingredient in Lecrolyn, is a mast cell stabilizer presented as an ophthalmic solution for ocular use. It is employed to treat allergic conjunctivitis, seasonal allergic eye disease, and other mast cell‑mediated ocular inflammation in patients who experience ocular itching, redness, and swelling due to allergic triggers and require prescription eye therapy.

GNH USA supplies Lecrolyn as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance across EU and global markets.

Lecrolyn, a mast cell stabilizer, is used to manage ocular allergic conditions by preventing mast cell degranulation.

Allergic conjunctivitis: alleviates ocular itching, redness, tearing, and swelling by stabilizing conjunctival mast cells. Seasonal allergic eye disease: provides symptom control during pollen or allergen exposure through inhibition of histamine release. Mast cell‑mediated ocular inflammation: reduces inflammatory mediator release, helping to preserve corneal clarity and comfort. Vernal keratoconjunctivitis: helps control chronic allergic inflammation of the cornea and conjunctiva, reducing photophobia and mucus discharge.

Topical ocular administration of Sodium Cromoglicate may be associated with local adverse reactions, most of which are mild and transient.

Common Side Effects: - Burning or stinging sensation after drop instillation. - Temporary blurred vision. - Mild conjunctival redness or irritation. - Increased tearing or watery eyes.

Serious or Rare Side Effects: - Severe allergic reaction such as angioedema or anaphylaxis. - Corneal edema or ulceration. - Persistent eye pain with possible vision loss. - Significant rise in intra‑ocular pressure.

When using Lecrolyn, certain precautions should be observed to ensure safety and therapeutic effectiveness.

- Hypersensitivity: discontinue use if signs of allergic reaction occur. - Ocular surgery: inform surgeon of use, as the drug may affect healing. - Contact lenses: avoid wearing lenses for at least 15 minutes after instillation. - Symptom monitoring: seek medical advice if symptoms worsen or persist beyond a few days. - Pregnancy and lactation: use only if clearly needed and prescribed after risk assessment. - Store at room temperature: keep in original container, protect from light and moisture.

Sodium Cromoglicate may interact with other ophthalmic agents, influencing efficacy or tolerability.

Major Interactions (Avoid): - Concurrent use with topical ocular anesthetics may increase corneal irritation. - Simultaneous administration with other mast cell stabilizers can heighten local sensitivity.

Moderate Interactions (Monitor Closely): - Combination with corticosteroid eye drops may mask signs of infection. - Use with antihistamine eye drops may provide additive relief but requires monitoring for excessive dryness. - Co‑administration with systemic antihistamines does not require dose adjustment but should be noted.